Shots:
Avery spoke about the study design and the new data obtained from the P-III VOYAGER PAD trial evaluating Xarelto + Aspirin to treat peripheral artery disease presented at the 72nd ACC 2023
The data demonstrated that the treatment with the Xarelto vascular dose following LER had a 33% reduction in acute limb ischemia and a 15%…
VIEWPOINTS
Shots:
Anas spoke about revenue cycle management in the healthcare sector and the traditional challenges in the healthcare RCM
He also elaborated on how the evolving technologies can help to overcome the challenges in healthcare revenue cycle management
The interview shows how Santechture is developing smart AI-based and cloud-based solutions to help healthcare providers develop…
Shots:
Eric shared the results from the first immunological results of its PDC-LUNG-101 P-I/II trial with PDC*lung01 which is the company’s cancer vaccine candidate for Non-Small Cell Lung Cancer
The results were presented at ESMO-IO 2022 elaborating on the safety, tolerability, immunogenicity, and preliminary clinical activity of the drug candidate
The interview shows PDC*line’s vision…
Shots:
Monica spoke about the new data from its multiple sclerosis therapies portfolio presented at the 38th ECTRIMS meeting
The highlights from the presentation were the safety and efficacy results of Vumerity, patient-reported outcomes from the treatment with Tysabri, and posters highlighting advances in digital health initiatives
The interview shows how Biogen develops, and delivers…
Shots:
Gregory initially spoke about the Attralus licensing agreement with Ossianix’s brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease
He also talked about how Ossianix VNAR antibody-based brain shuttle TXP1 will help Attralus to deliver AT-04, its developmental PAR therapeutic candidate,…
Shots:
David first talked about Clarivate’s Highly Cited Researchers 2022 list. He said that the list picks out 6,938 individuals at universities, research institutes, and commercial organizations across 69 countries/regions
He also elucidated the methodology used by Clarivate to create the list and how the pharma companies can benefit from this list to strengthen their…
Shots:
Samiah Al-Zaidy spoke about the interim clinical data from Imagine-1, P-I/II trial of PBGM01 for GM1 gangliosidosis presented at the 19th Annual WORLDSymposium 2023
She also talked about how the presentation at WORLDSymposium contributed to raising awareness about GM1 Gangliosidosis which is a rare and fatal disease
The interview showcases Passage Bio’s mission to…
Shots:
Dr. Harmony gave the details about the positive 12-month findings from the P-IIIb SOLAR trial of the first and only complete long-acting injectable regimen Cabenuva vs. Biktarvy
She also talked about the comparison of the Cabenuva regimen with the other existing & developing products for HIV including the Biktarvy regimen
The interview gives an…
Shots:
Gina gave her views on the acceptance of the sBLA by the US FDA and the validation of the Type II Variation Marketing Authorization Application by the EMA for Opdivo as monotherapy for the treatment of patients with completely resected stage IIB or IIC melanoma
She also spoke on the epidemiology of melanoma and…
Shots:
Allyson gave a brief overview of Kalderos and spoke about a new portal designed for drug manufacturers to provide a more efficient way to process drug discount claims
She also elaborated on how this Drug Discount Management platform will help drug manufacturers to organize their discounts by taking this data out of Excel spreadsheets…

